In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.
|Published (Last):||19 January 2014|
|PDF File Size:||17.38 Mb|
|ePub File Size:||7.6 Mb|
|Price:||Free* [*Free Regsitration Required]|
Eur Heart J ; It has multiple theoretical benefits over VKA therapy including less intensive monitoring and fewer drug interactions. Concurrent medications that could alter activity of VKAs; 8. All these reasons can be grouped in three broad categories: Its role in prevention of stroke in patients unsuitable for VKA therapy, but maintained on aspirin therapy, was unknown. J Am Coll Cardiol ; Patients also needed to have at least one of the following risk factors for stroke: Dual therapy decreased rates of major vascular events at cost of increased major bleeding.
One may question each of these choices: In patients with atrial fibrillation thought to be unsuitable for anticoagulation with a vitamin K antagonist, does apixaban reduce risk for stroke or systemic embolism when compared to aspirin? With a mean follow-up of 1. This page was last modified on 3 Decemberat The primary outcome was stroke or systemic embolism. N Engl J Med ; Yet, these proportions reflect the current underuse of VKAs in multiple registries.
The AVERROES Trial – Clinical Implications
Did you know that your browser is out of date? Thus, a clear superiority of apixaban over aspirin was shown in terms of efficacy, with comparable safety.
Adverse event not related to avedroes during VKA therapy; 3. Usable articles Cardiology Neurology. Patients were eligible if they were 50 years of age or older and if they had atrial fibrillation that had been documented in the 6 months prior to enrollment or by lead electrocardiography on the day of screening. The New England Journal of Medicine. Dabigatran versus warfarin in patients with atrial fibrillation.
Connolly SJ, et al.
The AVERROES Trial – Clinical Implications
There were 51 primary outcome events in those randomised to apixaban 1. Other characteristics indicating risk of stroke too low to warrant treatment with VKAs; Apixaban is, at the time of writing, the best alternative to aspirin in patients deemed unsuitable for vitamin K antagonists.
There were 44 1. In patients with atrial fibrillation thought to be unsuitable candidates for anticoagulation with a vitamin K antagonist, apixaban signficantly reduced the risk of stroke and systemic embolism without increasing the risk of major bleeding or intracranial hemorrhage when compared to aspirin. AVERROES on the other hand has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of avfrroes, with surprisingly similar safety.
Presented as apixaban vs.
AVERROES – Wiki Journal Club
Mortality rates were 3. Don’t miss out Read your latest personalised notifications Ok, got it. The reasons that VKA therapy was unsuitable for the patient had to be documented in the study case report forms.
In addition, patients could not be receiving VKA therapy, either because it had been demonstrated unsuitable in their case or because it was expected to be unsuitable. To get the best experience using our acerroes we recommend that you upgrade to a newer version. There were 11 intracranial bleeds on apixaban and 13 on aspirin apixaban 1. Read your latest personalised notifications Sign in No account yet? Analyses are to time of first event.
Concurrent medications whose metabolism could be affected by VKAs; 9. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: This proportion was similar for both academic and community hospitals.
The median duration of follow-up was 1. A serious bleeding event during VKA therapy; 4.
Sign in to My ESC. N Engl J Med We will here briefly discuss aveeroes clinical implications of the trial. Statistics presented where given by the authors. Also, how does apixaban compare to aspirin rates of major bleeding?